Diquafosol tetrasodium - CAS 211427-08-6
Catalog number: B0084-437603
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H22N4Na4O23P4
Molecular Weight:
878.23
COA:
Inquire
Targets:
P2Y Receptor
Description:
Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-437603 50 mg $399 In stock
Bulk Inquiry
Brife Description:
A P2Y2 receptor agonist
Synonyms:
tetrasodium;[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; diquafosol; INS 365; INS-365; INS365
Solubility:
H2O: ≥ 32 mg/mL
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
OWTGMPPCCUSXIP-FNXFGIETSA-J
InChI:
1S/C18H26N4O23P4.4Na/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30;;;;/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30);;;;/q;4*+1/p-4/t7-,8-,11-,12-,13-,14-,15-,16-;;;;/m1..../s1
Canonical SMILES:
C1=CN(C(=O)NC1=O)C2C(C(C(O2)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OCC3C(C(C(O3)N4C=CC(=O)NC4=O)O)O)O)O.[Na+].[Na+].[Na+].[Na+]
1.Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep.
Sabater JR;Mao YM;Shaffer C;James MK;O'Riordan TG;Abraham WM J Appl Physiol (1985). 1999 Dec;87(6):2191-6.
The purpose of this study was to determine whether aerosolized INS316 (UTP) stimulates lung mucociliary clearance (MCC) in sheep and, if so, to compare its effects with INS365, a novel P2Y(2)-receptor agonist. In the first series of studies, we used a previously described roentgenographic technique to measure tracheal mucus velocity (TMV), an index of MCC, before and for 4 h after aerosolization of INS316 (10(-1) M and 10(-2) M) and INS365 (10(-1) M and 10(-2) M), or normal saline in a randomized crossover fashion (n = 6). In a second series of studies, we compared the ability of these agents to enhance total lung clearance. For these tests, the clearance of inhaled technetium-labeled human serum albumin was measured serially over a 2-h period after aerosolization of 10(-1) M concentration of each agent (n = 7). Aerosolization of both P2Y(2)-receptor agonists induced significant dose-related increases in TMV (P < 0.05) compared with saline. The greatest increase in TMV was observed between 15 and 30 min after drug treatment. The highest dose (10(-1) M) of INS316 produced a greater overall stimulation of TMV than did INS365 (10(-1) M). Both compounds, compared with saline, induced a significant increase in MCC (P < 0.
2.Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells.
Lee JH;Lee JS;Kim S;Lee JE Korean J Physiol Pharmacol. 2017 Mar;21(2):189-195. doi: 10.4196/kjpp.2017.21.2.189. Epub 2017 Feb 21.
This study aimed to compare the cellular toxicities of three clinically used dry eye treatments; 3% diquafosol tetrasodium and hyaluronic acid at 0.3 and 0.18%. A methyl thiazolyltetrazoiun (MTT)-based calorimetric assay was used to assess cellular proliferation and a lactate dehydrogenase (LDH) leakage assay to assess cytotoxicity, using Human corneal epithelial cells (HCECs) exposed to 3% diquafosol tetrasodium, 0.3% hyaluronic acid (HA), or 0.18% HA or 1, 6 or 24 h. Cellular morphology was evaluated by inverted phase-contrast light microscopy and electron microscopy, and wound widths were measured 24 h after confluent HCECs were scratched. Diquafosol had a significant, time-dependent, inhibitory effect on HCEC proliferation and cytotoxicity. HCECs treated with diquafosol detached more from the bottoms of dishes and damaged cells showed degenerative changes, such as, reduced numbers of microvilli, vacuole formation, and chromatin of the nuclear remnant condensed along the nuclear periphery. All significantly stimulated reepithelialization of HCECs scratched, which were less observed in diquafosol. Therefore, epithelial toxicity should be considered after long-term usage of diquafosol and in overdose cases, especially in dry eye patients with pre-existing punctated epithelial erosion.
3.Therapy for chronic obstructive pulmonary disease in the 21st century.
Donnelly LE;Rogers DF Drugs. 2003;63(19):1973-98.
Chronic obstructive pulmonary disease (COPD) is a common, smoking-related, severe respiratory condition characterised by progressive, irreversible airflow limitation. Current treatment of COPD is symptomatic, with no drugs capable of halting the relentless progression of airflow obstruction. Better understanding of the airway inflammation, oxidative stress and alveolar destruction that characterise COPD has delineated new disease targets, with consequent identification of novel compounds with therapeutic potential. These new drugs include aids to smoking cessation (e.g. bupropion) and improvements to existing therapies, for example long-acting rather than short-acting bronchodilators, as well as combination therapy. New antiproteases include acyl-enzyme and transition state inhibitors of neutrophil elastase (e.g. sivelestat and ONO-6818), matrix metalloprotease inhibitors (e.g. batimastat), cathepsin inhibitors and peptide protease inhibitors (e.g. DX-890 [EPI-HNE-4] and trappin-2). New antioxidants include superoxide dismutase mimetics (e.g. AEOL-10113) and spin trap compounds (e.g. N-tert-butyl-alpha-phenylnitrone). New anti-inflammatory interventions include phosphodiesterase-4 inhibitors (e.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products


CAS 367909-40-8 MRS 2279

MRS 2279
(CAS: 367909-40-8)

MRS 2279 is the first broadly applicable, selective and high affinity competitive antagonist radioligand for a P2Y receptor (Ki = 2.5 nM; IC50 = 51.6 nM).

CAS 104869-26-3 NF 157

NF 157
(CAS: 104869-26-3)

NF 157 is a P2Y11 receptor antagonist with IC50 value of 463 nM. It inhibits NAD+-induced activation of human granulocytes.

CAS 1309871-50-8 MRS 4062 triethylammonium salt

MRS 4062 triethylammonium salt
(CAS: 1309871-50-8)

MRS 4062 is a hP2Y4 agonist with EC50 value of 23 nM, EC50 value of 640 nM to P2Y2 receptor and EC50 value of 740 nM to P2Y6 receptor.

CAS 919351-41-0 AZD1283

AZD1283
(CAS: 919351-41-0)

AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/...

CAS 274693-27-5 Ticagrelor

Ticagrelor
(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

CAS 216657-60-2 AR-C 118925XX

AR-C 118925XX
(CAS: 216657-60-2)

AR-C126313, a thiouracil derivative, has been found to be a competitive P2Y2 receptor antagonist and could inhibit P2Y2 receptor-induced β-arrestin translocatio...

Prasugrel Maleic acid
(CAS: 389574-20-3)

Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.

CAS 1657025-60-9 PSB 1114

PSB 1114
(CAS: 1657025-60-9)

PSB 1114, a β,γ‐difluoromethylene derivative of 4‐thio‐UTP, is a potent, selective P2Y2 agonist (EC50 = 0.134 μM),with >60-fold selectivity versus P2Y4 and P2Y6...

Chemical Structure

CAS 211427-08-6 Diquafosol tetrasodium

Quick Inquiry

Verification code

Featured Items